Intellia Therapeutics(NASDAQ) NTLA

Intellia fixes broken genes to treat rare and severe diseases. It uses a tool called CRISPR to edit DNA directly. These one-time treatments aim to cure the cause of illness.

What is in the Pipeline?

• Lonvo-z (NTLA-2002): Investigational treatment for Hereditary Angioedema (HAE) designed to stop life-threatening swelling by editing genes in the liver; currently in Phase 3 clinical trials.
• Nex-z (NTLA-2001): Lead candidate for Transthyretin (ATTR) Amyloidosis aiming to halt a fatal protein-building disease through a single infusion; currently in Phase 3 development.
• Ex Vivo Programs: Cell therapies engineered outside the patient's body to treat leukemia and various autoimmune conditions.
• Platform Licenses: Intellectual property and tools provided to partners for developing new medicines for blood and eye disorders.

Growing the Genome Toolkit

• Acquired Rewrite Therapeutics Inc. in February 2022 to expand the company's genome editing capabilities with new DNA writing technology.
• Formed AvenCell Therapeutics, Inc. in July 2021 as a joint venture with Cellex and Blackstone Life Sciences to develop universal cancer therapies.
• Renewed a long-term partnership with Regeneron Pharmaceuticals, Inc. to co-develop treatments for hemophilia and other liver-focused diseases.
• Licensed genome editing technology to Kyverna Therapeutics, Inc. in December 2021 for the development of autoimmune disease treatments.

What Makes Intellia Stand Out

Intellia is the first company to move "in vivo" CRISPR treatments—where gene editing occurs directly inside the patient—into late-stage Phase 3 clinical trials. Its modular platform allows technical learnings from one program to be applied across its entire pipeline to accelerate development.

The Financial Scorecard

• Revenue reached $23 million in Q4 2025, up 78.8% from $12.9 million in Q4 2024.
• Net loss narrowed to $95.8 million in Q4 2025, a 25.7% improvement from the $128.9 million loss in Q4 2024.
• Operating cash flow reached negative $69.3 million in Q4 2025, a 18.7% improvement from negative $85.2 million in Q4 2024.
• Free cash flow reached negative $69.4 million in Q4 2025, up 19.5% from negative $86.2 million the previous year.

Bottom Line

Intellia has transitioned from a research-focused organization to a late-stage clinical developer preparing for its first commercial launch in 2027. Its focus on permanent gene-editing cures marks a significant shift away from traditional lifelong drug regimens.